Plus   Neg

Stock Alert: Inovio Pharma Falls 11%

Shares of Inovio Pharmaceuticals Inc. (INO) tanked 11% on Friday morning trade, ending a four-day growth streak.

The stock had on Thursday touched a 20-year high and gained more than 9-fold for a year-to-date period. The company on Tuesday had announced it secured a $71 million funding from the U.S. Department of Defense for the large-scale manufacture of its CELLECTRA 3PSP smart device and the procurement of CELLECTRA 2000 devices, which are used to deliver the COVID-19 vaccine INO-4800 directly into the skin.

The company's COVID-19 vaccine candidate INO-4800 is also under a phase I study in the U.S., with interim results expected to be available later this month.

A phase II/III efficacy trial is planned to begin this summer (July/August).

INO is currently trading at $27.62, down $3.63 or 11.62%, on the Nasdaq.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Department of Health and Human Services or HHS said it has secured most of the supply of COVID-19 drug remdesivir through September. The deal would allow American hospitals to purchase the antiviral drug in allocated amounts amid the spike in confirmed cases each day. HHS Secretary Alex Azar said, "President Trump has struck an amazing deal to ensure Americans have access to the first..." Novartis AG (NVS) agreed to pay $678 million to settle U.S. government charges it paid illegal kickbacks to doctors to induce them to prescribe its cardiovascular and diabetes drugs, the U.S. Department of Justice said in a statement. PG&E Corp. (PCG) said Wednesday that it has emerged from Chapter 11 bankruptcy protection, after implementing its financial restructuring plan that was previously approved by the U.S. Bankruptcy Court and state regulators.
Follow RTT